Heparin-induced thrombocytopenia and heart operation: Management with tedelparin

Anticoagulation for cardiopulmonary bypass in the infrequent clinical setting of thrombocytopenia associated with the use of unfractionated heparin is a very serious problem. We describe a case in which a low-molecular-weight heparin (tedelparin) was selected for this purpose based on a platelet agg...

Full description

Saved in:
Bibliographic Details
Published inThe Annals of thoracic surgery Vol. 59; no. 2; pp. 508 - 509
Main Authors Altés, Albert, Martino, Rodrigo, Gari, Mercè, Cámara, Maria Lluisa, Garín, Rosa, Casas, Juan-Ignacio, Fontcuberta, Jordi
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.02.1995
Elsevier Science
Subjects
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Cardiopulmonary Bypass
Dalteparin - therapeutic use
Female
Heart Valve Prosthesis
Heparin - adverse effects
Humans
Medical sciences
Middle Aged
Mitral Valve - surgery
Pharmacology. Drug treatments
Platelet Aggregation - drug effects
Platelet Aggregation Inhibitors - therapeutic use
Thrombocytopenia - chemically induced
Thrombocytopenia - diagnosis
Heart
Human
Thrombocytopenia
Toxicity
General anesthesia
Cardiovascular disease
Anticoagulant
Molecular weight
Cardiopulmonary bypass
Case study
Concomitant disease
Treatment
Low
Surgery
Heparin
Online AccessGet full text

Cover

More Information
Summary:Anticoagulation for cardiopulmonary bypass in the infrequent clinical setting of thrombocytopenia associated with the use of unfractionated heparin is a very serious problem. We describe a case in which a low-molecular-weight heparin (tedelparin) was selected for this purpose based on a platelet aggregation test, permitting adequate anticoagulation during cardiopulmonary bypass for valve replacement. This case report might help establish an adequate anticoagulation protocol when faced with a patient suffering from this condition.
ISSN:0003-4975
1552-6259
DOI:10.1016/0003-4975(94)00572-O